Tennant Company shares rise 1.25% intraday after FDA approval of PAPZIMEOS.

Tennant Company rose 1.25% during intraday trading, following the US FDA approval of PAPZIMEOS, a first and only FDA-approved therapy for the treatment of adults with Recurrent Respiratory Papillomatosis (RRP). The approval was announced during a call led by Helen Sabzevari, PhD, President and CEO of Precigen, with key participants including Phil Tennant, Chief Commercial Officer, and Harry Thomasian Jr., Chief Financial Officer.